BHC
Bausch Health Companies Inc. Health Care Pharmaceutical Preparations Russell 3000
$8.20Close
$3.0BMarket cap
$4.43 – $8.9152-week range
Late-januaryNext report · estimated
Highlights
Strengths
- Leading the market RS 87 · stronger than 87% of stocks over 12 months
- Accumulation up-day volume 1.8× down-day volume over 50 sessions
- Earnings growing EPS +140% year on year, faster than the quarter before (+68 pts)
Cautions
- Trend not confirmed 6 of 8 conditions · 150-day under the 200-day, 200-day not rising
- Extended 5.9 ATR above its 50-day average
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
8%
1wk
up 27.3%
price change
1mo
up 40.7%
price change
12-month return
up 24%
market up 11% ·
its own up 28%
F-score
—
— Not assessed
Altman Z
0.26
Elevated risk
P/E
19.4×
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
up 8.1%
EBIT / enterprise value
Cheaper than
93%
of the market · markedly cheap
Revenue growth
up 7%
year on year
EPS growth
up 140%
latest quarter · +68 pts
Sales growth
up 10%
latest quarter · -3 pts
ROE
—
return on equity
Free cash margin
up 10%
$1.0B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
6.4×
Interest cover
1.1×EBIT / interest
Trade setup
ATR%
5.3%
$0.44 a day · 2×ATR $7.32
RS
87 / 99
vs the universe
Trend
6 / 8
150-day under the 200-day, 200-day not rising
Relative volume
3.0×
vs 50-day average
Up/down volume
1.79
50 sessions
Implied move
—
no scheduled report
Trend template · 6 of 8
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$554.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Interest is covered, but thinly Earnings before interest cover the interest bill 1.1 times, leaving little room if profits fall.
- Heavily indebted Net debt is 6.4 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported
Oct 28, 2026
Results reaction
Oct 28, 2026+41% vs market2 sessions after results
Financials
- Net 2%
- Free cash 10%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.0B | $8.4B | $8.1B | $8.8B | $9.6B | $10.3B |
| Operating income | $676.0M | $450.0M | $454.0M | $963.0M | $1.5B | $1.8B |
| Net income | -$560.0M | -$948.0M | -$225.0M | -$592.0M | -$46.0M | $157.0M |
| Net margin | -7% | -11% | -3% | -7% | -0% | 2% |
| Earnings per share | -$1.58 | -$2.64 | -$0.62 | -$1.62 | -$0.12 | $0.42 |
| Free cash flow | $809.0M | $1.2B | -$946.0M | $817.0M | $1.3B | $1.0B |
| Free cash margin | 10% | 14% | -12% | 9% | 13% | 10% |
| Cash | $605.0M | $582.0M | $564.0M | $947.0M | $1.2B | $1.3B |
| Long-term debt | $23.9B | $22.7B | $20.3B | $21.9B | $18.9B | $20.6B |
| Shareholders' equity | $535.0M | -$106.0M | -$692.0M | -$1.0B | -$1.3B | -$554.0M |
| Shares outstanding | 355.42m | 359.41m | 361.90m | 365.24m | 367.84m | 370.53m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results ↗ |
| Jul 29, 2026 | Results ↗ |
| Jul 1, 2026 | Director or officer change · Regulation FD ↗ |
| May 19, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Mar 2, 2026 | Director or officer change ↗ |
| Feb 18, 2026 | Results ↗ |
| Jan 23, 2026 | Regulation FD ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Jan 2, 2026 | Material agreement · New obligation · Other events ↗ |
| Dec 29, 2025 | Material agreement · New obligation ↗ |
| Dec 23, 2025 | Other events ↗ |